Please login to the form below

Not currently logged in
Email:
Password:

US drug prices

This page shows the latest US drug prices news and features for those working in and with pharma, biotech and healthcare.

Trump budget targets rebates, out-of-pocket costs

Trump budget targets rebates, out-of-pocket costs

Nevertheless, it is a signal of intent from the US administration and contains a number of elements that will prick up the ears of the biopharma industry. ... The budget would fundamentally upset the successful Medicare drug benefit that has provided

Latest news

  • Senate grilling makes pharma CEOs squirm, but give little ground Senate grilling makes pharma CEOs squirm, but give little ground

    Yesterday’s much anticipated US Senate inquiry provided a welcome spectacle for anyone who enjoys seeing big pharma executives given a good scolding on their drug pricing tactics, but produced only ... They opposed the “international price index”

  • Fireworks likely at Senate drug pricing hearing today Fireworks likely at Senate drug pricing hearing today

    pharma division) debate drug prices with lawmakers at a time when major legislative reform seems to be looming. ... why drug prices in the US are the highest in the world.

  • CEOs agree to Congressional grilling on US drug prices CEOs agree to Congressional grilling on US drug prices

    as part of a probe into US drug prices. Chair of the Senate committee on finance, Republican Charles Grassley is a long-time critic of pharma pricing policies, and announced the ... It is just one of several bills aimed at reduce or contain drug prices

  • End to middlemen rebates a major shift in US drug pricing End to middlemen rebates a major shift in US drug pricing

    US opinion polls show many believe pharma to have the greatest responsibility for high prices, but the new measures address accusations of profiteering at pharmacy benefit managers (PBMs). ... There are many other proposals being put forward in

  • Reference price bill tabled in US House and Senate Reference price bill tabled in US House and Senate

    Both texts claim that the measures would reduce median drug prices in the US by around 43%, with even higher reductions in some cases. ... Khanna. “This bill will bring down drug prices by taking on monopolies and boosting prescription drug competition.

More from news
Approximately 6 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    US drug prices. In other news from the US, there are now expectations of a legislative stalemate following the mid‐term elections in early November. ... It is worth remembering that there are still a few areas where both political parties are prepared

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Trump had tweeted days before that Pfizer “should be ashamed that they have raised drug prices for no reason”, claiming they were “taking advantage of the poor and others unable to ... The Trump administration has also just floated the idea of

  • Deal Watch January 2017 Deal Watch January 2017

    bear on US drug prices and the possible revocation of Obamacare in part, if not in full.  In addition, early press coverage suggests that there may be an introduction of a ... 230. Cymabay. Kowa. Exclusive licence in the US. Arhalofenate for gout p3

  • Tracking comms trends: Europe in the global vanguard on value Tracking comms trends: Europe in the global vanguard on value

    But this is changing. President Obama, plus candidates Donald Trump and Hillary Clinton, have all proposed that Medicare should negotiate drug prices. ... More locally, US HMOs and insurance funds are using levels of HTA and deploying cost containment

  • Social media and inflation penalties for generic drugs Social media and inflation penalties for generic drugs

    US generic drug companies are under more scrutiny as the US public becomes more vocal . ... In reality, the omission of a similar inflation penalty for generics has allowed drug prices in that market to rise primarily unchecked.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics